Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742569 | 0.92 | MAOA (0.41) | MAOAMAOBKMT2AMEN1NFE2L2 | |
| SCHEMBL7167401 | 0.82 | CYP11B1 (0.38) | MAOAMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL7164646 | 0.80 | CA12 (0.44) | MAOBALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2599765 | 0.79 | TDP1 (0.35) | MAOBKMT2AATMALDH1A1LMNA | |
| SCHEMBL7163687 | 0.76 | F2 (0.39) | MAOBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL2980634 | 0.72 | NFE2L2 (0.38) | MAOAMAOBKMT2ANFE2L2AOC2 | |
| SCHEMBL10500420 | 0.72 | KMT2A (0.39) | MAOBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL1462548 | 0.72 | LMNA (0.40) | MAOAMAOBKMT2AMEN1ATM | |
| SCHEMBL9051513 | 0.72 | MAOA (0.42) | MAOAMAOBKMT2AMEN1NFE2L2 | |
| SCHEMBL6552309 | 0.71 | MAOB (0.39) | MAOAMAOBKMT2AMEN1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947504-B1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6555699-B2 | Antitumor and antirheumatic agents, high binding affinity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6433200-B1 | ANTITUMOR AND ANTIRHEUMATIC AGENTS, HIGH BINDING AFINITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY | CHUGEI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6326503-B1 | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-12-04 | — | — | US | disclosed |
| US-6184398-B1 | ANTITUMOR AGENTS AND TREATMENT OF RHEUMATIC CONDITIONS; HIGH BINDING ABILITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY; E.G.,1,3-DIHYDROXY-20-3-HYDROXY-3-METHYLBUTYLTHIO)-9,10-SECOPREGNA -5,7,10(19),16-TETRAENE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | VDR, CYP24A1, CYP2R1 | MAOA 4181/4885MAOB 3734/4885KMT2A 4427/4885 |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | VDR, CYP2R1, CYP24A1 | MAOA 3842/4885MAOB 3085/4885KMT2A 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.